Compass Pathways plc Depositary Receipt (CMPS)
COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript
COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript
COMPASS Pathways plc (CMPS) Q1 2026 Earnings Call Transcript
COMPASS Pathways plc (CMPS) Q1 2026 Earnings Call Transcript
Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?
Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.
What Makes COMPASS Pathways PLC Sponsored ADR (CMPS) a Strong Momentum Stock: Buy Now?
Does COMPASS Pathways PLC Sponsored ADR (CMPS) have what it takes to be a top stock pick for momentum investors? Let's find out.
How Much Upside is Left in COMPASS Pathways (CMPS)? Wall Street Analysts Think 136%
The mean of analysts' price targets for COMPASS Pathways (CMPS) points to a 136% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
COMPASS Pathways plc (CMPS) Discusses Clinical Trial Plans for PTSD and Commercial Preparations for Treatment-Resistant Depression Transcript
COMPASS Pathways plc (CMPS) Discusses Clinical Trial Plans for PTSD and Commercial Preparations for Treatment-Resistant Depression Transcript
COMPASS Pathways plc (CMPS) Q3 2025 Earnings Call Transcript
COMPASS Pathways plc ( CMPS ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Stephen Schultz - Senior Vice President of Investor Relations Kabir Nath - CEO & Director Teri Loxam - CFO, Principal Financial Officer & Principal Accounting Officer Lori Englebert - Chief Commercial Officer Steve Levine - Chief Patient Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Judah Frommer - Morgan Stanley, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Chi Wen Chin - TD Cowen, Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Sumant Kulkarni - Canaccord Genuity Corp., Research Division Presentation Operator Good morning, ladies and gentlemen, and thank you for standing by.
COMPASS Pathways Plc (CMPS) Presents At Cantor Global Healthcare Conference 2025 Transcript
COMPASS Pathways plc (NASDAQ:CMPS ) Cantor Global Healthcare Conference 2025 September 3, 2025 1:35 PM EDT Company Participants Kabir Nath - CEO & Director Guy Goodwin - Chief Medical Officer Steve Levine - Chief Patient Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Presentation Joshua Schimmer Biotech Equity Research Analyst All right. Welcome, everyone.
COMPASS Pathways plc (CMPS) Q2 2025 Earnings Call Transcript
COMPASS Pathways plc (NASDAQ:CMPS ) Q2 2025 Earnings Call July 31, 2025 8:00 PM ET Company Participants Guy Goodwin - Chief Medical Officer Kabir Kumar Nath - CEO & Director Lori Englebert - Chief Commercial Officer Stephen D. Schultz - Senior Vice President of Investor Relations Steve Levine - Chief Patient Officer Teri Loxam - CFO, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Chi Wen Chin - TD Cowen, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Judah C.
These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy?
Investors seeking stocks that can put up dramatic gains in a short amount of time can find what they're looking for in the biotechnology industry. Investment bank analysts on Wall Street have tagged a pair of pre-revenue businesses with price targets that are miles above their current stock prices.
COMPASS Pathways (CMPS) Upgraded to Buy: Here's Why
COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know
COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
